PMID- 8977310
OWN - NLM
STAT- MEDLINE
DCOM- 19970204
LR  - 20171116
IS  - 0014-2980 (Print)
IS  - 0014-2980 (Linking)
VI  - 26
IP  - 12
DP  - 1996 Dec
TI  - Effect of CD80 and CD86 blockade and anti-interleukin-12 treatment on mouse acute 
      graft-versus-host disease.
PG  - 3098-106
AB  - We investigated the efficacy of a combination of anti-CD80 and CD86 (CD80 + 86) 
      monoclonal antibodies (mAb), anti-interleukin (IL)-12 mAb, or both, for 
      prophylaxis in a mouse acute graft-versus-host-disease (GVHD) model. The 
      treatment with a combination of anti-CD80 + 86 mAb efficiently reduced the 
      lethality of GVHD, whereas mAb against either CD80 or CD86 alone had an effect. A 
      delay in lymphocyte reconstitution and GVHD-associated histological changes in 
      organs was observed at 30 days post-bone marrow transplantation (BMT) even in the 
      anti-CD80 + 86 mAb-treated mice, although these manifestations were resolved by 
      100 days. In vitro, host alloantigen-specific T cell proliferative responses and 
      generation of CTL were significantly reduced by anti-CD80 + 86 treatment. 
      Furthermore, anti-CD80 + 86 mAb preferentially inhibited the production of 
      interferon (IFN)-gamma, but not IL-4 and IL-10, when cultures were assayed at 21 
      days. Although the anti-IL-12 mAb treatment alone inhibited the generation of 
      cytotoxic T lymphocytes and IFN-gamma production in vitro, administration of 
      anti-IL-12 mAb in vivo reversed the beneficial effects of anti-CD80 + 86 
      treatment on host survival post-BMT. The adverse effect of anti-IL-12 treatment 
      seems to result from impairment of natural immunity and hematopoiesis, rather 
      than as a consequence of an incomplete blockade of T helper (Th)1 responses. Our 
      results suggest that the prevention of GVHD-induced death results from the 
      efficient blockade of Th1 cell activation by the anti-CD80 + 86 treatment. 
      However, further treatment is required for a complete prevention of GVHD, which 
      seems to be partly mediated by Th2 cells.
FAU - Saito, K
AU  - Saito K
AD  - Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan.
FAU - Yagita, H
AU  - Yagita H
FAU - Hashimoto, H
AU  - Hashimoto H
FAU - Okumura, K
AU  - Okumura K
FAU - Azuma, M
AU  - Azuma M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Eur J Immunol
JT  - European journal of immunology
JID - 1273201
RN  - 0 (Antibodies, Blocking)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antigens, CD)
RN  - 0 (B7-1 Antigen)
RN  - 0 (B7-2 Antigen)
RN  - 0 (Cd86 protein, mouse)
RN  - 0 (Membrane Glycoproteins)
RN  - 130068-27-8 (Interleukin-10)
RN  - 187348-17-0 (Interleukin-12)
RN  - 207137-56-2 (Interleukin-4)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Acute Disease
MH  - Animals
MH  - Antibodies, Blocking/*pharmacology/therapeutic use
MH  - Antibodies, Monoclonal/*pharmacology/therapeutic use
MH  - Antigens, CD/*immunology
MH  - B7-1 Antigen/*immunology
MH  - B7-2 Antigen
MH  - Female
MH  - Graft vs Host Disease/mortality/*prevention & control/*therapy
MH  - Immunization, Passive
MH  - Interferon-gamma/antagonists & inhibitors/biosynthesis
MH  - Interleukin-10/antagonists & inhibitors/biosynthesis
MH  - Interleukin-12/biosynthesis/*immunology
MH  - Interleukin-4/antagonists & inhibitors/biosynthesis
MH  - Membrane Glycoproteins/*immunology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C3H
MH  - Mice, Inbred C57BL
EDAT- 1996/12/01 00:00
MHDA- 1996/12/01 00:01
CRDT- 1996/12/01 00:00
PHST- 1996/12/01 00:00 [pubmed]
PHST- 1996/12/01 00:01 [medline]
PHST- 1996/12/01 00:00 [entrez]
AID - 10.1002/eji.1830261241 [doi]
PST - ppublish
SO  - Eur J Immunol. 1996 Dec;26(12):3098-106. doi: 10.1002/eji.1830261241.